Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 13 Oct 2023 for Protagenic Therapeutics, Inc.\new, €6,150. Read the official filing
Filing timeline
BuySaleAlexander K. Arrow
Insider track record
Disclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-9.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Alexander K. Arrow: trading record in brief
All filings by Alexander K. Arrow on record concern Protagenic Therapeutics, Inc.\new, in the capacity of finance chief. Over a trading history stretching from 29 April 2021 to 12 October 2023, the count stands at 3 filings.
No open-market sale appears; the market trades are 3 purchases worth €24k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2023 alone, the filings show 1 purchase and no sales.
Half of the purchases are above €6,150 and half below. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days.
The latest filing, published on 13 October 2023, reports an open-market purchase of €6,150 in Protagenic Therapeutics, Inc.\new. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Alexander K. Arrow
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
8,000 shares@ US$0.8124.2% of flowPTIX Common StockSEC:0001493152-23-037136:0
Canonical exit: 10 Jan 2024 (T+90)
23,000 shares@ US$0.711.32% mcap80.4% of flowPTIX Common StockSEC:0001493152-22-014338:0
Canonical exit: 15 Aug 2022 (T+90)
1,000 shares@ US$2.298.0% of flowPTIX Common StockSEC:0001493152-21-010335:0
Canonical exit: 28 Jul 2021 (T+90)
3 of 3 declarations
